Salim Yazji

Salim Yazji is a declared insider of Oncternal Therapeutics, Inc. (senior executive), with filings sourced from SEC (Form 4). We count 9 filings; the first trade dates from 3 January 2022 and the latest from 3 January 2024.

The open-market record is one-sided, with 4 purchases worth €22k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 5 share grants.

In size, the median ticket on the buying side is €2,585. 4 out of 4 purchases came within 30 days of a purchase by at least one other insider of the same company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

On 5 January 2024 came the latest disclosure, a share grant for €8,951 in Oncternal Therapeutics, Inc. The most recent open-market purchase was published on 14 April 2023, 1,288 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.